Announced Fri, 24 Jul · 18:08 IST
Vimta Labs Q1 FY27 earnings call transcript filed; revenue up 13.7% YoY
Mgmt Guided Margin ImprovementMgmt Guided Margin PressureOrder Pipeline DisclosedMgmt Evaded Key QuestionInvestor Communications View source PDF
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹568.00
prior close
₹576.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+0.8+0.7+0.9——————————
Up moveDown movePending
AI summary
Vimta Labs filed the Q1 FY27 earnings call transcript. Total income rose 13.7% YoY to INR1,129 million. EBITDA grew 16% to INR411 million with 36.4% margin. PAT was up 11.4% YoY at INR210 million. Company is net debt-free with INR628 million cash. The Biologics segment secured its first order and facility is operational. Margins moderated QoQ due to facility expenses, new labor laws, and rupee appreciation. Management is confident about 20-25% growth aspiration.
Likely market impact
Steady Q1 with double-digit growth, strong margins, and net debt-free balance sheet. Biologics entry opens a new growth avenue.